Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 343

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 343
---
 other revenues related to commercial ELEVIDYS supply to Roche and royalty revenue from Roche. The Company’s CEO, as the CODM, manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and in line with the Company's strategic goals. The Company’s accounting policies associated with segment information are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting Pronouncements to the consolidated financial statements.The measure of segment profit or loss that the CODM uses to allocate resources and assess performance is the Company’s consolidated net income (loss). The CODM uses consolidated net income (loss) to assess the segment’s overall profitability. The table below includes information about the Company’s segment, including significant segment expenses, and a reconciliation to net income (loss): 

F-39

        For the Year Ended December 31,

        2024

        2023

        2022

        (in thousands)

        Total revenues
         
        $
        1,901,979

        $
        1,243,336

        $
        933,013

        Segment expenses and other segment items

        Cost of sales (excluding amortization of in-licensed rights)

        319,099

        150,343

        139,989

        Compensation and other personnel expenses

        335,830

        319,080

        256,382

        Manufacturing expenses

        329,011

        345,826

        466,111

        Clinical trial expenses

        163,565

        187,289

        135,838

        Facility- and technology-related expenses (excluding depreciation and amortization)

        106,281

        88,559

        71,700

        Research and development- other (excluding non-cash items) (a)

        108,597

        118,727

        117,171

        Selling, general and administrative- other (excluding non-cash items) (b)

        226,598

        181,310

        124,948

        Roche collaboration reimbursement

        (127,107
        )

        (106,885
        )

        (117,807
        )

        Other segment items (c)

        (30,449
        )

        (49,129
        )

        (11